<DOC>
	<DOC>NCT01181050</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to evaluate the clinical efficacy of a single dose of NNC0142-0002 administered to subjects with active rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis of RA meeting the American College of Rheumatology 1987 (ACR1987) criteria, obtained at least three months prior to dosing with the trial product Subjects with active RA having a Disease Activity Score (DAS28CRP) of 4.5 or more, at least five tender and five swollen joints (can be the same), including one swollen wrist or at least two swollen ipsilateral metacarpophalangeal (MCP) joints (second to fifth) Concomitant treatment with methotrexate (MTX) (7.525 mg/week) for at least 12 weeks, with stable dose for at least 4 weeks prior to dosing Ability to be examined by Magnetic Resonance Imaging (MRI) Having failed no biologic therapies for RA and no more than two nonbiologic disease modifying antirheumatic drugs Chronic inflammatory autoimmune disease other than RA (rheumatoid arthritis) Any ongoing chronic or active infectious disease or microbial infection requiring systemic oral or intravenous treatment against infection within 1 month prior to trial start Body mass index (BMI) below or equal to 18 or above or equal to 40 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>